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Available online 26 February 2014AbstractThe aim of this study was to investigate the influence of interleukin (IL)-6 gene polymorphisms on upper respiratory tract infection (URTI)
incidence. To this end, 100 healthy elite male athletes participating in the study were classified as either healthy or prone to frequent URTI.
Blood samples and DNA isolation, multiplex polymerase chain reaction, and Taqman real-time polymerase chain reaction were carried out.
Genomic DNA was extracted from peripheral leukocytes of whole blood samples using the QIAmp DNA Blood Mini Kit according to the
manufacturer’s protocols. For comparison of the distribution of genotypes between the two groups and for estimating odds ratios for URTI
susceptibility in relation to the IL-6 polymorphism, Pearson’s c2 and logistic regression methods were used, respectively. The IL-6-174 genotype
distribution differed between athletes with URTI and healthy athletes (c2 ¼ 11.68, p ¼ 0.003). The IL-6 low-expression genotype (CC), relative
to the other two genotypes combined (GC þ GG), was associated with a tendency for an increased likelihood of frequent URTI (odds ratio: 3.33,
95% confidence interval: 1.40e7.92; p ¼ 0.006). In conclusion, findings from this study have identified a potential role of genetic variation in
influencing the risk for URTI in athletic populations and single nucleotide polymorphisms in the IL-6 genes were associated with an altered risk
profile. These measures may have a predictive value in the identification of individuals who are more likely to experience recurrent infections
when exposed to high physical stress in the areas of athletic endeavor.
Copyright  2014, The Society of Chinese Scholars on Exercise Physiology and Fitness. Published by Elsevier (Singapore) Pte Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Cytokine; Elite athletes; Gene expression; GG genotype; Single nucleotide polymorphismsIntroduction
There is incontrovertible evidence that regular physical ac-
tivity contributes to the primary and secondary prevention of
several chronic diseases and is associated with a reduced risk of
premature death. There appears to be a graded linear relation
between the volume of physical activity and health status, such
that the most physically active people are at the lowest risk.1
However, epidemiological evidence shows that high vol-
ume and/or high intensity of training, particularly in endurance* Corresponding author. Department of Physical Education & Sport
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access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-ndathletes, can be associated with an increased risk of devel-
oping respiratory tract syndromes, including upper respiratory
tract infection (URTI).2 The incidence of URTI in both highly
trained and healthy untrained individuals is known to increase
in response to increases in activity. This risk of illness in
response to exercise has been modeled by the J Curve. This
model suggests that individuals engaging in moderate physical
activity are at lower risk of illness compared with sedentary
individuals. Conversely, excessive volumes of strenuous
endurance exercise may suppress immune function, thereby
increasing the risk of illness.3
Specific diffrences in the expression of cytokine genes may
account for differences in susceptibility to URTI (and other
infectious diseases) by influencing the function of immune
cells or the cytokine response to pathogens.4,5 In addition, pro-cise Physiology and Fitness. Published by Elsevier (Singapore) Pte Ltd. This is an open
/4.0/).
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differ between healthy and illness-prone athletes, and may
account in part for differences in the history of upper respi-
ratory illness between individual athletes.6
Some investigations found that heavy physical activity pro-
duces a rapid, transient increase in cytokine production and en-
tails increases in both proinflammatory [interleukin (IL)-2, IL-5,
IL-6, IL-8, and tumor necrosis factor (TNF)-a] and anti-
inflammatory (IL-1 receptor antagonist and IL-10) cytokines.
They mediate communication within and between cells, organs,
and organ systems throughout the body in immune, inflammatory,
and several other responses.7,8 Upregulation of inflammatory
cytokines, such asTNF-a, IL-1b, IL-6, and IL-10, and a cytokine-
mediated inflammatory response has also been documented as
being responsible for the severity of respiratory tract infections.9
IL-6 is a typical pleiotropic cytokine that plays roles in the
immune, endocrine, nervous, and hematopoietic systems, and
on bone metabolism.10 It has the ability to stimulate B-cell
differentiation, activate thymocytes and T cells for differenti-
ation, activate macrophages, stimulate hepatocytes to produce
acute-phase proteins, and activate natural killer cells. IL-6 also
possesses anti-inflammatory properties. In T cells, IL-6 con-
fers significant effects on proliferation, survival, and T helper
1/2 responses.10
Cytokines play a pivotal role in the regulation of the type
and magnitude of the immune response, and the polymorphic
nature of the cytokine genes may confer flexibility on the
immune response.11 All genes encoding cytokines involved in
the modulation of inflammatory responses are candidate genes
for determination of the human genetic background that is
responsible for interindividual differences in susceptibility and
outcome of sepsis.11,12 Examination of the regulation of
cytokine expression at the genetic level may prove important
in understanding the substantial interindividual differences in
cytokine responses to exercise, as well as individual differ-
ences in susceptibility to URTI.6
The influence of cytokine gene polymorphisms on gene
expression and disease has been addressed at two levels of
research: studies using in vitro gene expression, and those
involving in vivo disease associations.13 These studies attempt to
identify immunogenetic markers for a given disease. Association
is sought between specific cytokine gene polymorphisms and
clinical outcome by direct comparison of individual cytokine
genotypes and the clinical features of the disease (e.g., suscep-
tibility, duration, and severity). The a priori involvement of
dysregulation of a specific cytokine or receptor in the disease is
usually, though not always, the rationale for selecting a cytokine
or cytokine receptor gene for analysis. Using these and other
clues, many studies have identified statistically significant asso-
ciations between cytokine alleles and disease.13
Several investigations have examined the influence of
cytokine gene single nucleotide polymorphisms (SNPs) on the
incidence of infectious illness and patient prognosis. For
example, Doyle et al14 reported that individuals with IL-6-174
C/C genotype had more days with URTI and higher symptom
scores, compared with carriers of the G allele. In other studies,
there was an association between IL-6-174 G/C SNP and a riskof URTI.15,16 The IL-6 gene is located at chromosome 7p21.
Common polymorphisms have been described and the most
studied is the promoter polymorphism -174 G/C (rs1800795),
which has an influence on the transcription of the IL-6 gene
and plasma levels of IL-6.17 The C allele has been found to be
associated with lower levels of plasma IL-6 in healthy in-
dividuals and lower expression after lipopolysaccharide or IL-
1 stimulation in HeLa cells.17
In spite of the increasing studies affirming potential clinical
implications of functional polymorphisms, investigators are
not aware of any efforts to assess the role of genetic variation
being responsible for differences in incidence of URTI in
athletes, or individual differences in cytokine responses to
exercise. The primary purpose of this study was to investigate
comparison of the frequency of SNPs in IL-6 cytokine gene
between healthy athletes and athletes prone to frequent URTI.
MethodsParticipantsOne hundred healthy elite male athletes who were engaged
in regular sports training (predominantly endurance-based
activities such as running, cycling, swimming, triathlon, and
other sports) volunteered to participate in the study. Partici-
pants ranged from state active to national and Asian athletes.
Participants were needed to complete a comprehensive health-
screening questionnaire prior to starting the study and had not
taken any medication in the 8 weeks prior to the study. All
participants were wholly informed about the rationale for the
study. Participants provided written consent to take part in the
study, which had earlier received the approval of Tabriz
Medical University Ethical Advisory Committee (Tabriz, Iran;
No. 91134 date: November 13, 2012).
Participants could be included if they were currently healthy,
had been involved in endurance training for at least 2 years,
engaged in at least three sessions, and at least 3 hours of total
moderate/high-intensity training time per week,4 and were be-
tween 18 years and 35 years of age. One hundred participants
completed the study with baseline characteristics
(mean standard deviation) as follows: age 23.97 5.93 years,
body weight 71.85  7.12 kg, body height 177.70  7.80 cm,
body mass index 22.77  2.09 kg/m2, and self-reported profes-
sional training experience 5.11  3.52 years.Study designThe study was an evaluation of the influence of IL-6 gene
polymorphisms on URTI incidence. As a result of the diffi-
culty in interpreting the biological influences of genetic dif-
ferences in small populations, we used a genotype-specific
clinical model and participants were selected based on exer-
cise experience. They were requested to continue with their
normal training programs during the 12-month subsequent
study period and they completed a health (URTI symptoms)
questionnaire on a weekly basis. The illness symptoms listed
on the questionnaire were: sore throat, catarrh in the throat,
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cle soreness, joint aches and pains, weakness, headache, and
loss of sleep. The non-numerical ratings of light, moderate, or
severe symptoms were scored as 1, 2, or 3, respectively, to
provide a quantitative means of data analysis and the total
symptom score for every participant each week was calculated
by multiplying the total number of days each symptom was
experienced by the numerical ratings symptom severity. In any
given week, a total symptom score 12 was taken to indicate
that a URTI was present. This score was chosen because to
achieve it, a participant would have to record at least three
moderate symptoms lasting for 2 days or two moderate
symptoms lasting for at least 3 days in a given week. A single
URTI episode was defined as a period during which the
weekly total symptom score was 12 and separated by at least
1 week from another week with a total symptom score 12.4
Therefore, the participants were classified as either healthy or
prone to frequent URTI (notated as illness-prone) based on in-
formation collected via the questionnaire. In keeping with the
average annual incidence of upper respiratory illness previously
reported in the general population (2.4 episodes per year),6 ath-
letes reporting two or fewer episodes of URTI in the previous 12-
month period were grouped as healthy (n ¼ 53), and athletes
reporting three or more episodes of URTI in the previous 12-
month period were grouped as illness-prone (n ¼ 47). Partici-
pants with lower respiratory tract symptoms (cough, wheeze, or
chest pain) were excluded from participation. Characteristics of
the two classification groups are shown in Table 1.Genotyping analysesBlood samples and DNA isolation, multiplex polymerase
chain reaction (PCR), and conventional allele-specific PCRwereTable 1
Characteristics of healthy and illness-prone groups including mean (standard
deviation) number of self-reported episodes of URTI in the preceding
12-month period and the proportion of each group and athletes participating in
different sports.a
Characteristics Groups
Healthy
(2 URTI)
Illness-prone
(3 URTI)
n 53 (53) 47 (47)
Age (y) 23.85  3.24 24.11  3.88
Body weight (kg) 72.92  6.91 70.64  6.73
Height (cm) 178.15  6.11 177. 19  5.62
BMI (kg/m2) 22.98  1.96 22.53  2.23
Professional training experience (y) 5.64  3.34 4.51  2.91
URTI episodes/y 1.00  0.73 3.06  0.25
Duration of the symptoms
of URTI in every episode (d)
3.45  2.15 5.38  0.90
Sports type
Runners 11 (20.75%) 11 (23.40%)
Swimmers 17 (32.08%) 12 (25.53%)
Cyclists 1 (1.89%) 7 (14.89%)
Triathlon 13 (24.53%) 8 (17.02%)
Other endurance sports 11 (20.75%) 9 (19.16%)
Data are presented as n (%) or mean  SD.
URTI ¼ upper respiratory tract infection.
a Number of athletes participating in different sports is shown.performed. Genomic DNA was extracted from peripheral leu-
kocytes of whole blood samples using the QIAmp DNA Blood
Mini Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s protocols.18 The polymorphism of the IL-6 promoter re-
gion at -174 was studied by PCRerestriction fragment length
polymorphism. The region of interest was amplified by PCR
using primers 5-TGACTTCAGCTTTACTTTGT-3 and 5-
AATCTTAATAAGGTTTCCA-3.The reactionwas carried out in
a final volume of 25mLcontaining 1.5mmol/LMgCl2, 0.2mmol/
L each dNTP, 0.2 mmol/L each primer, and 1 U Taq polymerase
(Cinagene, Tehran, Iran). DNA was amplified during 30 cycles
with an initial denaturation of 10 minutes at 94C and a final
extension of 10 minutes at 72C. The cycle program consisted of
1 minute denaturation at 94C, 1 minute and 35 seconds
annealing at 62C, and 1 minute extension at 72C.19 The PCR
product was digested by adding 10UNlaIII restriction enzyme at
37C overnight, the digested fragments were separated by
agarose gel electrophoresis, and detected by ethidium bromide
staining. The polymorphism was due to a replacement of G by C
at position -174. The identified genotypes were named according
to the presence or absence of the enzyme restriction sites, so
NlaIII (GG), (GC), and (CC) were homozygote for the presence
of the site (153/40 bp), and heterozygote for the presence/absence
of the site (193/153/40), and homozygote for the absence of the
site (198 bp), respectively.Statistical analysisData were expressed as percentages or mean  standard
deviation. Prior to statistical analysis to eliminate the feasi-
bility of any population bias, HardyeWeinberg equilibrium of
the allele distribution was tested. Pearson’s c2 was used for
comparison of the distribution of genotypes between the two
groups. For each polymorphism, genotypes were classified as
high, moderate, or low based on documented effects on
cytokine gene expression. Logistic regression method was
used to estimate odds ratios, expressed with their 95% confi-
dence intervals for URTI susceptibility in relation to the IL-6
polymorphism. Statistical significance was set at p  0.05.
The statistical analyses were performed using SPSS version
19.0 (SPSS Inc., Chicago, IL, USA).
Results
Genotype distribution of the IL-6-174 polymorphism in
URTI-prone and healthy athletes is shown in Table 2. Two
groups were in HardyeWeinberg equilibrium, with significant
c2 values for the observed and expected genotype frequencies.
The IL-6-174 genotype distribution differed between athletes
with URTI and healthy athletes (c2 ¼ 11.68, p ¼ 0.003). The
IL-6 high-expression genotype was observed at a greater fre-
quency in the healthy group compared with the illness-prone
group (64.15% vs. 14.89%).
The predictive value of the polymorphism in assessing the
classification as illness-prone athletes demonstrated that the
IL-6 low-expression genotype (CC), relative to the other two
genotypes combined (GC þ GG), was associated with a
Table 2
Distribution of interleukin (IL)-6-174 C/G single nucleotide polymorphisms in
athletes with upper respiratory tract infection and healthy athletes and results
of c2 analysis.
Genotype Groups c2 p
Healthy Illness-prone
Genotype Level of gene expression n ¼ 53 n ¼ 47
CC Low 3.77 31.92
11.68 0.003GC Moderate 32.08 53.19
GG High 64.15 14.89
Data are presented as %.
18 F. Zehsaz et al. / Journal of Exercise Science & Fitness 12 (2014) 15e19tendency for an increased likelihood of frequent URTI (odds
ratio: 3.33, 95% confidence interval: 1.40e7.92; p ¼ 0.006).
Discussion
This study examined the role of an IL-6 promoter SNP at
-174C/G in URTI susceptibility. Our findings suggest an as-
sociation between common SNPs at IL-6 genes and URTI in
well-trained athletes. Other studies have demonstrated that the
expression of IL-6 is related to its allelic variant. It is known
that the IL-6 gene has about 50 SNPs in its promoter region,
like the variants -597 G/A, -572 G/C, -373 A/T, and -174 G/C,
among others. The -174 G/C SNP in the promoter region of
the IL-6 gene has gained considerable interest because it has
been associated with a variety of disease states.20 Several
studies have questioned the functional role of the -174 G/C
SNP in the production of IL-6 both in vivo and in vitro. The
change of guanine bases to cytosine (G/ C) at position -174
seems to affect the transcription of the IL-6 gene and therefore
the plasma levels of this cytokine in young, elderly, and
centenarian individuals.21 Functional SNPs in the proin-
flammatory cytokine genes including IL-6 (174G/C) and TNF-
a (308G/A), that affect the production of anti-inflammatory
cytokines, such as IL-10 have been associated with both sus-
ceptibility to outcomes of infectious diseases and sepsis.22e24
We observed that IL-6-174 polymorphism CC was associ-
ated with susceptibility to URTI, and participants with the GG
genotype had a lower incidence of URTI than those with the
CC genotypes. The IL-6-174 GG homozygous carrier state has
already been associated with diminished susceptibility to acute
and chronic inflammatory diseases.25 This finding is in
agreement with a report that showed that the -174 GG geno-
type was associated with improved survival in sepsis.26
Mahdaviani et al27 found that GG and GC genotypes of IL-6
at position -174 lead to high production of IL-6, whereas
CC genotype leads to low production of this cytokine. Higher
IL-6 levels were observed in the group of elderly women with
the GG genotype, as also observed in a recent Brazilian
study.21 Another small study reported that high IL-6 expres-
sion genotype was associated with reduced symptom severity
in response to experimentally induced respiratory syncytial
virus infection.28 As reported in other studies, higher IL-6
concentrations were positively correlated in both phase and
magnitude with the expressed viral symptom/sign complex
leading to the expectations that the high production IL-6(-174) phenotype would predict higher IL-6 concentrations
and consequently greater illness magnitudes.14
In interpreting these results, IL-6 G/C promoter poly-
morphism has functional significance. The -174G/C poly-
morphism is contained in a sequence bearing partial nucleotide
homology with the Sma- and Mad-related protein (Smad)4
binding element. Smad4 is a transcription factor that partici-
pates in the signal transduction cascade of transforming growth
factor-b and activin to inhibit the expression of proin-
flammatory molecules. The C allele at the variant position in
the consensus-binding element binds Smad4 more effectively,
and hence represses IL-6 transcription, whereas substitution by
a G allele at this position decreases the binding efficiency by
90% and therefore increases transcription of the IL-6 gene.29
These results are in contrast to data presented by Jones
et al.30 who have reported that high plasma IL-6 concentra-
tions in patients and healthy individuals were associated with
the C allele and CC genotype rather than with the G allele and
the GG or GC genotype. Another recent report showed an
association of the IL-6 high expression genotype and an
increased risk for frequent URTI.6 Some studies have also
indicated that IL-6-174G/C polymorphism does not signifi-
cantly affect plasma IL-6 concentrations.31,32 Contradictory
reports about the role of IL-6 polymorphisms in URTI sus-
ceptibility may not be surprising. Those discrepancies might
be explained either by the diverse ethnic background of the
two studied populations or by the different mechanisms
possibly involved in the development of URTI.
We found that the GG homozygous genotype at the -174
locus of the IL-6-174 gene was the dominant genotype in
healthy athletes (64.15%). Also, these data suggest that the IL-
6 CC genotype affects URTI susceptibility, whereas the GG
genotype may have a protective effect. It may be possible to
identify those athletes who have a high susceptibility to in-
fections with future genetic testing. The initial strategy for
athletes suffering fatigue should be to reduce or cease training
for a short period of time to allow recovery. It is important
during this reduction in training to ensure appropriate nutri-
tion, and avoid energy, carbohydrate, or protein deficits. If
fatigue persists or infections recur despite rest and nutrition
then further medical investigation is warranted.25
The findings from this study have identified a potential role of
genetic variation in influencing the risk for URTI in athletic
populations, and SNPs in the IL-6 genes were associated with an
altered riskprofile. Thesemeasuresmayhave a predictivevalue in
the identification of individualswho aremore likely to experience
recurrent infections when exposed to high physical stress in the
areas of athletic and military endeavor.4 Hence, the cause of the
increased incidence of infection in athletes is likely to be multi-
factorial: a variety of stressors (physical, psychological, envi-
ronmental, or nutritional) can suppress immune function,33 and
these effects, together with increased exposure to pathogens, can
make the athlete more susceptible to infection.
This possibility is further supported by evidence demon-
strating that a combination anti-inflammatory/antibacterial
throat spray used after a marathon was able to reduce the
post-race incidence and severity of URTI in distance runners.6
19F. Zehsaz et al. / Journal of Exercise Science & Fitness 12 (2014) 15e19Preventive infection-control measures should be taken to avoid
infection. These include regular hand washing, minimal con-
tact with sick persons, and the avoidance of sharing personal
items. Adequate rest and proper nutrition are vital to a healthy
immune system.34,35
In conclusion, in this study we demonstrated the functional
significance of -174G/C of IL-6 in association of the IL-6
(-174) CC genotype with URTI susceptibility. Uncovering
and understanding the genetic determination of the suscepti-
bility to infection offers the chance of developing valuable
diagnostic tools and new therapeutic approaches in URTI.
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